Bay Street News, May, 2024

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic […]

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in […]

–   60% response rate observed among 10 evaluable patients –   Favorable safety profile in 26 patients enrolled as of the […]

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive […]

– Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients […]

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T […]

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session […]

CALGARY, Alberta, May 23, 2024 (GLOBE NEWSWIRE) — Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased […]

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has […]

ELKHART, Ind., May 23, 2024 (GLOBE NEWSWIRE) — THOR Industries, Inc. (NYSE: THO) today announced that the date for its […]